<DOC>
	<DOCNO>NCT00103285</DOCNO>
	<brief_summary>This randomized phase III trial study different combination chemotherapy regimens compare well work treat patient newly diagnose acute lymphoblastic leukemia . Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine whether substitution three intensified phase post-Induction treatment standard phase improve event free survival ( EFS ) child SR-average acute lymphoblastic leukemia ( ALL ) . II . Determine whether substitution intensify Consolidation standard Consolidation improve EFS child SR-average ALL . III . To determine whether addition four dose percutaneous endoscopic gastrostomy ( PEG ) asparaginase , give every three week Consolidation Interim Maintenance phase , improve EFS child SR-low ALL . SECONDARY OBJECTIVES : I . Identify potentially modifiable factor associate impaired health relate quality life ( HRQOL ) different period therapy patient SR-average enrol standard risk ALL study . II . Determine critical time period future intervention study mitigate adverse HRQOL outcomes occur . III . Correlate day 29 minimal residual disease ( MRD ) EFS overall survival ( OS ) patient treat regimen . IV . Correlate early marrow response day 29 MRD status . V. To improve outcome identify additional high risk patient Day 29 MRD treatment fully augment Berlin-Frankfurt-Munster ( BFM ) . VI . To examine relative contribution genetic factor early treatment response outcome compare outcome patient without TEL-AML1 fusion triple trisomy low level MRD end Induction treat identical therapy standard arm SR-low SR-average trial . OUTLINE : This 2-part , partially randomize , multicenter study . Patients stratify accord early response study induction therapy ( rapid early response [ standard risk ( SR ) -low SR-average acute lymphoblastic leukemia ( ALL ) ] v slow early response [ SR-high ALL ] ) . After completion induction therapy proceed part II therapy , patient assign 1 3 group base stratification . PART I : INDUCTION THERAPY : All patient receive cytarabine intrathecally ( IT ) day 1 ; vincristine IV day 1 , 8 , 15 , 22 ; dexamethasone IV orally ( PO ) twice daily ( BID ) day 1-28 ; pegaspargase intramuscularly ( IM ) ( may give IV 1 2 hour ) day 4 , 5 , 6 ; methotrexate IT day 8 29 ( day 15 22 patient CNS3 disease ) . Patients Down syndrome ( DS ) receive leucovorin calcium PO 48 60 hour dose methotrexate IT . Patients assessed response day 29 . Patients M1 bone marrow AND minimal residual disease ( MRD ) &lt; 0.1 % OR MRD &gt; = 0.1 % &lt; 1 % proceed therapy part II . Patients M2 bone marrow OR M1 bone marrow AND MRD &gt; = 1 % proceed extend induction therapy . Patients M3 bone marrow remove study . EXTENDED INDUCTION THERAPY : Patients receive dexamethasone IV PO BID day 1-14 ; vincristine IV day 1 8 ; pegaspargase IM day 4 , 5 , 6 ; daunorubicin hydrochloride IV 15 minute 2 hour day 1 . Patients M1 bone marrow MRD &lt; 1 % extended induction therapy proceed therapy part II . Patients M2 M3 bone marrow extend induction therapy remove study . PART II : GROUP 1 ( SR-low ALL ) : Patients randomize 1 2 treatment arm . ARM I : STANDARD CONSOLIDATION THERAPY : Patients receive vincristine IV day 1 ; mercaptopurine PO day 1-28 ; methotrexate IT day 1 , 8 , 15 . Patients Down syndrome ( DS ) receive leucovorin calcium ( PO ) 48 60 hour dose methotrexate IT . STANDARD INTERIM MAINTENANCE THERAPY : Patients receive vincristine IV day 1 29 ; dexamethasone IV PO BID day 1-5 29-33 ; mercaptopurine PO day 1-50 ; methotrexate PO day 1 , 8 , 15 , 22 , 29 , 36 , 43 , 50 ; methotrexate IT day 29 . Patients DS receive leucovorin calcium PO 48 60 hour dose methotrexate IT . STANDARD DELAYED INTENSIFICATION ( DI ) THERAPY : Patients receive vincristine IV day 1 , 8 , 15 ; dexamethasone IV PO BID day 1-21 ; doxorubicin hydrochloride IV 15 minute 2 hour day 1 , 8 , 15 ; pegaspargase IM day 4 , 5 , 6 ; cyclophosphamide IV 30 minute day 29 ; cytarabine IV subcutaneously ( SC ) day 29-32 36-39 ; thioguanine PO day 29-42 ; methotrexate IT day 1 29 . Patients DS receive dexamethasone IV PO BID day 1-7 15-21 leucovorin calcium PO 48 60 hour dose methotrexate IT . ARM II : EXPERIMENTAL CONSOLIDATION THERAPY : Patients receive vincristine , mercaptopurine , methotrexate , leucovorin calcium arm I pegaspargase IM day 1 22 . EXPERIMENTAL INTERIM MAINTENANCE THERAPY : Patients receive vincristine , dexamethasone , mercaptopurine , methotrexate PO , methotrexate IT arm I pegaspargase IM day 15 36.Standard DI therapy : Patients receive standard DI therapy arm I . GROUP 2 ( SR-average ALL ) : Patients randomize 1 4 treatment arm . ARM I : Patients receive standard consolidation therapy , standard interim maintenance therapy , standard DI therapy group 1 , arm I . ARM II : STANDARD CONSOLIDATION THERAPY : Patients receive standard consolidation therapy group 1 , arm I. Augmented interim maintenance therapy : Patients receive vincristine IV methotrexate IV day 1 , 11 , 21 , 31 , 41 ; pegaspargase IM day 2 22 ; methotrexate IT day 1 31 . Patients DS receive leucovorin calcium PO 48 60 hour dose methotrexate IT . Augmented DI therapy : Patients receive vincristine IV day 1 , 8 , 15 , 43 , 50 ; dexamethasone IV PO BID day 1-21 ; doxorubicin hydrochloride IV 15 minute 2 hour day 1 , 8 , 15 ; pegaspargase IM day 4 , 5 , 6 AND day 43 ; cyclophosphamide IV 30 minute day 29 ; cytarabine IV SC day 29-32 36-39 ; thioguanine PO day 29-42 ; methotrexate IT day 1 , 29 , 36 . Patients DS receive dexamethasone day 1-7 15-21 leucovorin calcium PO 48 60 hour dose methotrexate IT . ARM III : INTENSIFIED CONSOLIDATION THERAPY : Patients receive cyclophosphamide IV 30 minute day 1 29 ; cytarabine IV SC day 1-4 , 8-11 , 29-32 , 36-39 ; mercaptopurine PO day 1-14 29-42 ; vincristine IV day 15 , 22 , 43 , 50 ; pegaspargase IM day 15 43 ; methotrexate IT day 1 , 8 , 15* , 22* . Patients DS receive leucovorin calcium PO 48 60 hour dose methotrexate IT* . NOTE : *Patients CNS3 disease diagnosis receive methotrexate day 15 22 leucovorin calcium . STANDARD INTERIM MAINTENANCE THERAPY : Patients receive standard interim maintenance therapy group 1 , arm I . STANDARD DI THERAPY : Patients receive standard DI therapy group 1 , arm I . ARM IV : INTENSIFIED CONSOLIDATION THERAPY : Patients receive intensified consolidation therapy group 2 , arm III . AUGMENTED INTERIM MAINTENANCE THERAPY : Patients receive augment interim maintenance therapy group 2 , arm II . AUGMENTED DI THERAPY : Patients receive augment DI therapy group 2 , arm II . GROUP 3 ( SR-high ALL ) : Patients receive follow therapy : Intensified consolidation therapy : Patients receive intensified consolidation therapy group 2 , arm III . AUGMENTED INTERIM MAINTENANCE* THERAPY : Patients receive augment interim maintenance therapy group 2 , arm II . Treatment repeat every 56 day 2 course . NOTE : *As Amendment # 7 , SR-High patient currently receive AIM 1 therapy complete phase therapy proceed ADI 1 therapy originally plan include Capizzi methotrexate AIM 1 . Upon completion ADI 1 , patient receive second Interim Maintenance phase high-dose methotrexate ( IM HD ) rather Capizzi methotrexate . Patients proceed ADI 2 Maintenance . AUGMENTED DI* THERAPY : Patients receive augment DI therapy group 2 , arm II . Treatment repeat every 56 day 2 courses** . NOTE : *As Amendment # 7 , SR-High patient currently receive ADI 1 therapy complete phase therapy originally plan . Upon completion ADI 1 , patient receive second Interim Maintenance phase IM HD . Patients proceed ADI 2 Maintenance . NOTE : **Patients CNS3 disease diagnosis also undergo cranial radiotherapy day 29-33 36-40 course 2 ; patient receive methotrexate day 36 , thioguanine , leucovorin calcium . MAINTENANCE THERAPY : All patient receive vincristine IV day 1 , 29 , 57 ; oral dexamethasone twice daily day 1-5 , 29-33 , 57-61 ; oral methotrexate day 8 , 15 , 22 , 29 , 36 , 43 , 50 , 57 , 64 , 71 , 78 ; oral mercaptopurine day 1-84 ; methotrexate IT* day 1 . Courses repeat every 84 day total 2 year start interim maintenance therapy female patient 3 year start interim maintenance therapy male patient . NOTE : *SR-High CNS3 patient receive maximum 23 intrathecal treatment females 26 intrathecal treatment male . After completion study treatment , patient follow every 1-2 month 2 year , every 3 month 1 year , every 6-12 month 2 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>Patients must enrol AALL03B1 prior enrollment AALL0331 Initial white blood cell ( WBC ) &lt; 50,000/ul Newly diagnose Bprecursor acute lymphoblastic leukemia Standardrisk ( SR ) disease meet 1 follow criterion : SRaverage age WBC No unfavorable feature Rapid early responder ( RER ) day 15 CNS 1 2 Minimal residual disease ( MRD ) negative day 29 Trisomies 4 , 10 , 17 TELAML1 translocation RER CNS2 allow SRlow age WBC No unfavorable feature RER day 15 MRD negative day 29 CNS1 Favorable cytogeneticstrisomies 4 , 10 , 17 TELAML translocation SRhigh Unfavorable feature meet â‰¥ 1 follow criterion : MLL rearrangement RER Steroid pretreatment CNS3 Slow early responder morphology MRD Patients Down syndrome allow Patients overt testicular disease eligible study , may eligible AALL0232 Patients shall prior cytotoxic chemotherapy exception steroid intrathecal cytarabine ; intrathecal chemotherapy cytarabine allow prior registration patient convenience ; usually do time diagnostic bone marrow venous line placement avoid second lumbar puncture ; ( Note : central nervous system [ CNS ] status must determine base sample obtain prior administration systemic intrathecal chemotherapy , except steroid pretreatment Patients receive prior steroid therapy may eligible AALL0331 study Patients contraindication additional asparaginase therapy , follow Induction , eligible Standard RiskLow study , remove protocol therapy end Induction Patients assigned standard riskaverage group follow Induction meet HRQOL Age diagnosis &gt; = 2 year ( note restrictive age range therapeutic component study ) At least one parent read comprehension English Spanish language validate survey exist Diagnosis one institution participate limited institution correlative study A parent legal guardian must sign write informed consent/parental permission patient All institutional , Food Drug Administration ( FDA ) , National Cancer Institute ( NCI ) requirement human study must meet</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>9 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>